Braveheart Bio (BRVE) Director Christopher Viehbacher Buys Stock

What Happened
Christopher Viehbacher, a director of Braveheart Bio (BRVE), reported two acquisitions. On 2026-08-07 he purchased 83,333 shares in an open-market or private purchase at $18.00 per share for a total of $1,499,994. On 2026-08-05 he received an award/derivative grant of 30,000 shares (reported at $0.00), reflecting a stock-option-type award.

Key Details

• Transaction dates and amounts:
  • 2026-08-07: Purchase (Code P) — 83,333 shares @ $18.00 = $1,499,994.
  • 2026-08-05: Award/Grant (Code A, derivative) — 30,000 shares @ $0.00.
• Vesting/award terms: Footnote states the shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service.
• Beneficial ownership disclaimer: Reporting person disclaims beneficial ownership except to the extent of any pecuniary interest (per footnote).
• Shares owned after the transactions: Not disclosed in the provided filing details.
• Filing timeliness: Report filed 2026-08-07 for a primary transaction dated 2026-08-05 — filed within the two-business-day window required for Form 4 (timely).

Context

• Purchase vs. award: The purchase (P) is a direct cash acquisition of common shares (~$1.5M outlay). The award (A) appears to be an option-style grant that vests over time and is not an immediate transfer of vested shares.
• For retail investors: Direct insider purchases can be informative because they represent the insider buying stock with personal funds; award grants are common compensation and vesting schedules mean those shares are contingent on continued service.